A Phase 2 interventional study of EVO756, Dose 1 and EVO756, Dose 2 in Migraine, sponsored by Evommune, Inc.. Recruiting at 45 sites in 4 countries. Open to participants aged 18 Years to 64 Years. Per ClinicalTrials.gov, last updated 2026-11-13.
Sponsored by Evommune, Inc. · Phase 2, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 696 studies in Migraine Disorders with a site in United States — 93 open to participants now, 115 under way, 27 of them phase 3. Migraine Disorders · United States.
Among the 696 studies in Migraine Disorders with a site in United States, this one is the 147th largest by planned enrollment of the 609 interventional ones that give a count, is one of 36 that started in 2026, is one of 90 in phase 2, reaches primary completion later than 59 of the 114 other live ones, and was the 677th registered.
1,658 studies on the registry are indexed under Migraine Disorders; 339 are open to participants now.
Browse Migraine Disorders studies →93 of the 696 studies in Migraine Disorders with a site in United States are open now. Recruiting first, the newest first:
Salvia BioElectronics · Sites in United States
Ages 22–84
University of Colorado, Denver · Sites in United States
Ages 12–17
Columbia University · Sites in United States
Ages 18–55
TriGemX Bio, Inc. · Sites in United States
Ages 18–75
University of North Carolina, Chapel Hill · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 217 Migraine Disorders studies recruiting now, 66 (30%) set no upper age limit and 136 (63%) stop at 75 or younger; 44 take children under 18; 37 take healthy volunteers.
This study: 18 Years to 64 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
696 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 66 · Phase 2 113 · Phase 3 151 · Phase 4 101
First in 1999; this study’s year is marked. 36 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 330 is above the median of 80 across 1,269 interventional studies indexed under Migraine Disorders.
Median enrollment 78 across the 609 interventional studies, 195 across the 84 observational. Of the 526 that completed or were terminated, 305 (58%) have results posted.
This tab as a report to print or save as PDF → With an account.
344 of 696 have an industry lead sponsor. The 10 most frequent:
Evommune, Inc. is the lead sponsor of 6 studies on the registry; 1 is open to participants now.
Evommune, Inc. has 1 study filed under Migraine Disorders — fewer than ten, so there is no comparison to draw.
47 of the studies in Migraine Disorders with a site in United States that are under way reach primary completion within a year, 11 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06641466Phase 3PfizerA Study to Learn About the Study Medicine Called Rimegepant in Women When Used for Intermittent Prevention of Menstrual Migraine | 2026-11-29 |
| NCT07645924Phase 3TriGemX Bio, Inc.A Study to Evaluate the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of Migraine | 2027-02 |
| NCT05598723Phase 3Naval Medical Center Camp LejeuneBOTOX® vs. XEOMIN® for Chronic Migraine | 2027-02-24 |
| NCT07018700Phase 3Merz Therapeutics GmbHA Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Episodic Migraine | 2027-03 |
| NCT07018713Phase 3Merz Therapeutics GmbHA Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Chronic Migraine | 2027-03 |
Add all 47 to your calendar (.ics) → With an account.
Among the 696 studies in Migraine Disorders with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study will evaluate the efficacy and safety of EVO756 against placebo in adults with migraine.
Key Inclusion Criteria:
Key Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Orally administered EVO756, Dose 1 (Daily)
Drug: EVO756, Dose 1
Orally administered EVO756, Dose 2 (Daily)
Drug: EVO756, Dose 2
Placebo control (Daily)
Drug: Placebo
Orally administered EVO756, Dose 1 (Daily)
Orally administered EVO756, Dose 2 (Daily)
Placebo Control (Daily)
Mean change from baseline in the number of monthly migraine days (MMD)
Time frame: Last month of the 12-week treatment period
Mean change from baseline in the number of MMD
Time frame: Weeks 4, 8, and across the treatment period (up to 12-weeks)
Mean change from baseline in the number of monthly headache days (MHD)
Time frame: Weeks 4, 8, 12, and across the treatment period (up to 12-weeks)
Proportion of subjects achieving ≥50% and ≥75% reduction in MMD
Time frame: Weeks 4, 8, 12, and across the treatment period (up to 12-weeks)
Proportion of subjects achieving ≥50% and ≥75% reduction in MHD
Time frame: Weeks 4, 8, 12, and across the treatment period (up to 12-weeks)
Mean change from baseline in monthly acute migraine medication use days
Time frame: Weeks 4, 8, 12, and across the treatment period (up to 12-weeks)
Occurrence of treatment emergent adverse events (TEAE) and serious adverse events (SAE)
Time frame: through Week 16
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Plan to share: No
No publications or documents are linked to this record.
Started Jul 2026 (actual). Primary completion is estimated for Oct 2027, 15 months after the start.
Of 43 industry-sponsored phase 2 interventional studies under Migraine Disorders, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 20. This study's planned 15 months is above that.
Counting every sponsor, half of 73 studies reached it within 15 months; a quarter within 11 and three quarters within 30.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: EVO756
Evommune, Inc.